Specifically, it has been demonstrated that EPOR activation is able to antagonize trastuzumab therapeutic effect in vitro, thanks to the activation of a proliferative signaling pathway overlapping with ERBB2 pathway [29] and that EPOR-positive breast cancer patients display a reduced response to tamoxifen [37]. Here, ERBB2 is linked to breast cancer.